Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: Correlates with expression and quantification on metastases using 64Cu-plerixafor PET (Oncotarget (2018) 9:77 (34641-34641) DOI: 10.18632/oncotarget.19945)

Abstract

This article has been corrected: On page 73395, the following sentences have been updated to read, "Dosimetry for 64Cu-plerixafor calculated from this single patient gave an Effective Dose of 0.283 rem/mCi, and a total of 2.43 rem from the dose of 8.6 mCi. The organs that contributed the most to the Effective Dose were the liver and bone marrow (0.0606 and 0.0760 rem/mCi, respectively)". Similar to results in mice, the liver had the highest uptake of the tracer, with unbound tracer excreted through the kidneys [31, 32]. Significant uptake was also seen in organs of the immune system, including spleen, vertebral bodies (bone marrow), and lymph nodes (Figure 4 and Supplementary Figure 6). Of additional interest, uptake of 64Cu-plerixafor was absent from a number of vertebral bodies in the thoracolumbar spine that were within the region of prior radiation therapy (Figure 4 and Supplementary Figure 6). Dosimetry for 64Cu-plerixafor calculated from this single patient gave an Effective Dose of 0.283 rem/mCi, and a total of 2.43 rem from the dose of 8.6 mCi. The organs that contributed the most to the Effective Dose were the liver and bone marrow (0.0606 and 0.0760 rem/mCi, respectively). PET/CT sections (Figure 4B) showed variable uptake in the multiple pulmonary nodules.